

## **PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

### **Outer Carton**

#### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Footvax

#### **2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Contains ten strains of inactivated *Dichelobacter nodosus* with an oil adjuvant.

One dose of 1 ml contains:

<i>D. nodosus</i> serotypes A, B1, B2, C, D, E, F, G, H	10 µg pili each
<i>D. nodosus</i> serotype I	5 x 10 <sup>8</sup> cells

<u>Preservative:</u> Thiomersal	0.015% w/v
---------------------------------	------------

#### **3. PHARMACEUTICAL FORM**

Emulsion for Injection

#### **4. PACKAGE SIZE**

20 ml  
50 ml  
250 ml

20 doses  
50 doses  
250 doses

#### **5. TARGET SPECIES**

Sheep.

#### **6. INDICATION(S)**

Footrot vaccine for sheep.

#### **7. METHOD AND ROUTE(S) OF ADMINISTRATION**

**Dose:** 1 ml by subcutaneous injection.  
**Read instructions before use.**

## 8. WITHDRAWAL PERIOD

**Withdrawal period:** Zero days.

## 9. SPECIAL WARNING(S), IF NECESSARY

### **Operator Warnings:**

To the user: This product contains mineral oil. Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the doctor: This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

## 10. EXPIRY DATE

EXP:

Once opened use immediately.

## 11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2 °C to 8 °C).

Do not freeze.

Protect from light.

## 12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read instructions before use.

## 13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

*[Distribution category]*

For Animal Treatment only.

**POM-VPS**

To be supplied only on veterinary Prescription.

## 14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

**MA holder**

MSD Animal Health UK Ltd.  
Walton Manor  
Walton  
Milton Keynes  
MK7 7AJ

**Distributor in Northern Ireland**

Intervet Ireland Ltd.  
Magna Drive,  
Magna Business Park  
Citywest Road  
Dublin 24

**16. MARKETING AUTHORISATION NUMBER**

Vm 01708/4553

**17. MANUFACTURER'S BATCH NUMBER**

Batch no:

## **PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

### **Label**

#### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Footvax

#### **2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

One dose of 1 ml contains:

*D. nodosus* serotypes: A, B1, B2, C, D, E, F, G, H 10 µg pili each and *D. nodosus* serotype I 5 x 10<sup>8</sup> cells and Thiomersal.

#### **3. PHARMACEUTICAL FORM**

Emulsion for Injection

#### **4. PACKAGE SIZE**

20 doses

50 doses

250 doses

#### **5. TARGET SPECIES**

Sheep.

#### **6. INDICATION(S)**

Footrot vaccine for sheep.

#### **7. METHOD AND ROUTE(S) OF ADMINISTRATION**

**Route:** SC.

**Read package leaflet before use.**

#### **8. WITHDRAWAL PERIOD**

**Withdrawal period:** Zero days.

#### **9. SPECIAL WARNING(S), IF NECESSARY**

Read package leaflet before use.

#### **10. EXPIRY DATE**

Expiry:

## **11. SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated (2–8 °C).  
Do not freeze.  
Protect from light.  
Keep the container in the outer carton.

## **12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Read package leaflet before use.

## **13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE**

*[Distribution category]*

For animal treatment only.

POM-VPS

## **14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

## **15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Read package leaflet before use.

## **16. MARKETING AUTHORISATION NUMBER**

Vm 01708/4553

## **17. MANUFACTURER’S BATCH NUMBER**

Batch no.

**PACKAGE LEAFLET FOR:**

**Footvax  
Emulsion for injection.**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND  
OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR  
BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

MSD Animal Health UK Ltd.  
Walton Manor  
Walton  
Milton Keynes  
Buckinghamshire  
MK7 7AJ

Manufacturers for the batch release<sup>1</sup>:

MSD Animal Health UK Limited  
Walton Manor, Walton, Milton Keynes  
Buckinghamshire, MK7 7AJ  
United Kingdom

Intervet International B.V.

Wim de Körverstraat 35  
5831 AN Boxmeer  
The Netherlands

<sup>1</sup> The printed package leaflet will state the name and address of the manufacturer responsible for the release of the concerned batch only.

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Footvax  
Emulsion for injection.

**3. STATEMENT OF THE ACTIVE SUBSTANCE (S) AND OTHER INGREDIENTS**

One dose (1 ml) contains:

**Active ingredients:**

<i>Dichelobacter nodosus</i> serotype A	10 µg pili
<i>Dichelobacter nodosus</i> serotype B1	10 µg pili
<i>Dichelobacter nodosus</i> serotype B2	10 µg pili
<i>Dichelobacter nodosus</i> serotype C	10 µg pili
<i>Dichelobacter nodosus</i> serotype D	10 µg pili
<i>Dichelobacter nodosus</i> serotype E	10 µg pili
<i>Dichelobacter nodosus</i> serotype F	10 µg pili

<i>Dichelobacter nodosus</i> serotype G	10 µg pili
<i>Dichelobacter nodosus</i> serotype H	10 µg pili
<i>Dichelobacter nodosus</i> serotype I	5 x 10 <sup>8</sup> cells

**Excipients:**

Thiomersal (Preservative)	0.015%
Light mineral oil NF (adjuvant)	60%
Manide oleate (adjuvant)	4.5%

#### 4. INDICATION(S)

For the active immunization of sheep as an aid to the prevention of footrot and reduction of lesions of footrot caused by serotypes of *Dichelobacter nodosus*.

#### 5. CONTRAINDICATIONS

Do not vaccinate sheep within 6–8 weeks of shearing.

Do not use in lactating dairy sheep.

Do not vaccinate ewes in the period of 4 weeks before lambing to 4 weeks after lambing.

#### 6. ADVERSE REACTIONS

The vaccine may cause a reaction at the site of injection. This may range from a slight swelling from about 24 hours after injection, to a well defined lump of about 3 cm diameter 8 days after injection. These may further increase in size to 5 or even 8 cm diameter but these swellings generally remain inactive and may resolve completely within 4-6 weeks. Frequently swellings persist for at least ten weeks. Occasionally, however, these swellings may be large, painful and unsightly, with the formation of abscesses which may burst and discharge, particularly if any contaminating skin bacteria are introduced at the time of injection. Even so, partial or complete resolution within ten weeks of inoculation can be expected.

Reactions to second doses develop more slowly but the formation of necrotic lesions is rare. Occasionally abscesses may be noted on macroscopic examination of injection sites. Subcutaneous necrosis and inflammation may be noted on microscopic examination of injection sites.

Occasional hypersensitivity reactions may occur. In such cases, an appropriate dose of adrenalin and/or antihistamines should be administered without delay.

On rare occasions variable incidence of generalised lameness has been reported in vaccinated sheep. This is thought to be due to a local immunological reaction in the feet and is transitory in nature, occurring within 24 hours of vaccination and normally persisting for no more than 48 hours. Treatment is seldom necessary.

If you notice any serious effects or other effects not mentioned in this leaflet, please

inform your veterinary surgeon.

## **7. TARGET SPECIES**

Sheep.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Dose: 1 ml

### **Administration:**

Initial Course: Two doses, 6 weeks apart by subcutaneous injection. The site for injection is on the side of the neck 2–3 inches behind the ear.

Thoroughly shake the vaccine before use.

### **Vaccination programmes:**

These should be tailored to meet individual flock requirements which will vary from season to season according to the actual or likely incidence of footrot.

Wherever possible 'whole flock' vaccination programmes should be adopted. By this means disease incidence in the flock will decline and subsequent disease risk from the environment will be greatly reduced.

### **Prevention programme:**

Commence vaccination with a single dose of vaccine. Further doses of vaccine will be required according to the flock disease status and/or the climatic conditions. If, after 4-6 weeks significant levels of disease remain in the flock or climatic conditions conducive to footrot persist, administer a further dose. Otherwise delay this dose until conditions favour re-emergence of the disease. Subsequent doses should also be administered according to prevailing conditions. Thus, with severe and constant disease challenge, revaccination may be necessary at 4-5 monthly intervals; conversely under favourable conditions revaccination may be delayed until the incidence of disease challenge increases or climatic conditions worsen.

It should be noted that these adverse conditions tend to occur in the UK between March and May and between October and December thus, vaccination should normally be completed shortly before these periods if problems are anticipated.

### **Treatment programme:**

A single dose of vaccine should be given to the flock immediately the disease becomes apparent. For maximum effect, treatment with Footvax should be combined with the use of a footbath and antibiotic treatment.

Revaccination should be as stated in the prevention programme, which should then be continued on the farm as the key element of the overall flock foot care programme.



## 9. ADVICE ON CORRECT ADMINISTRATION

As the vaccine contains an oil adjuvant it is rather viscous. It will aid administration in cold weather if the vaccine is gently warmed by immersion in warm water (not hot) for 3-4 minutes before use.

Syringes and needles should be sterilised before use and the injection made through an area of clean, dry skin, taking strict precautions against contamination in order to reduce the possibility of abscess formation.

## 10. WITHDRAWAL PERIOD(S)

Zero days.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C to 8 °C).

Protect from light.

Do not freeze.

Once opened use immediately.

Do not use after the expiry date stated on the label and carton.

## 12. SPECIAL WARNING(S)

### **Special warnings for each target species**

Sheep destined for show or sale should not be vaccinated within the previous 6 months because of the occurrence of a well defined, inactive lump at the site of injection.

### **Special precautions for use in animals**

Not applicable.

### **Special precautions to be taken by the person administering the veterinary medicinal product to animals**

#### *To the user:*

This product contains mineral oil.

Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.

If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.

If pain persists for more than 12 hours after medical examination, seek medical advice again.

*To the doctor:*

This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

**Use during pregnancy or lactation**

Can be used during pregnancy.

Do not use in lactating dairy sheep.

**Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except those mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.

**Overdose (symptoms, emergency procedures, antidotes), if necessary**

When the vaccine is given at twice the recommended dose a reaction similar to that described in section 6 should be expected.

In some cases skin lesions with overt pus accumulation or slight necrosis develop. This necrotic skin lesion and pus accumulation occurs less frequently following a second injection. There are no adverse clinical signs in animals following treatment with 2x dose. There is no specific antidote.

**Incompatibilities**

Do not mix with any other veterinary medicinal products.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

November 2021

**15. OTHER INFORMATION**

For animal treatment only.

**Pack sizes:**

20 ml, 50 ml or 250 ml.

Not all pack sizes may be marketed.

**MA number:** Vm 01708/4553

**Legal category:**

POM-VPS

To be supplied only on veterinary prescription.

**Distributor in Northern Ireland:**

Intervet Ireland Ltd.

Magna Drive

Magna Business Park

Citywest Road

Dublin 24

Approved 02 December 2021

A handwritten signature in black ink, appearing to read 'A. Hunter.', is positioned below the approval date.